Clinical trial
A Single-centre, Open-label, Three-period Study of the Pharmacokinetic Effect of PA21 on Digoxin in Healthy Male and Female Adults
NCT01477411 is registered in ClinicalTrials.gov with Vifor Pharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-centre, Open-label, Three-period Study of the Pharmacokinetic Effect of PA21 on Digoxin in Healthy Male and Female Adults
- Lead sponsor
- Vifor Pharma
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 30, 2011
- Completion date
- January 31, 2012
- Enrollment
- 42 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
drug interaction potentiation